利用MRI R2*鉴别胰腺内副脾与胰腺神经内分泌肿瘤
回顾性分析20例胰腺内副脾与20例胰腺神经内分泌肿瘤患者的MRI,比较基于R2*的脾脏质量比(MSR)与增强MRI、ADC MSR诊断标准的敏感度和特异度;R2*标准(0.9≤R2* MSR≤1.7)敏感度高于增强MRI和ADC标准,特异度相近。
要点
- 胰腺内副脾在T2WI、增强晚期动脉期和门脉期及DWI上多与脾脏等信号,较胰腺神经内分泌肿瘤更常见。
- 胰腺内副脾的ADC MSR较低、R2* MSR较高,与胰腺神经内分泌肿瘤相比差异有统计学意义。
- R2* MSR标准(0.9≤R2* MSR≤1.7)鉴别胰腺内副脾与胰腺神经内分泌肿瘤的敏感度高于增强MRI和ADC标准,特异度相近。
核心结论
- 鉴别胰腺内副脾与胰腺神经内分泌肿瘤时,R2*的敏感度高于增强MRI和ADC,特异度与二者相近。
研究设计与样本
- 回顾性研究,由两名放射科医师(R1和R2)回顾性审阅20例胰腺内副脾和20例胰腺神经内分泌肿瘤患者的MRI,共40例患者(中位年龄54岁,四分位距43-65岁;男24例、女16例)。
关键影像表现/征象
- 胰腺内副脾在T2WI、晚期动脉期、门脉期和扩散加权成像上表现为与脾脏等信号的比例高于胰腺神经内分泌肿瘤(p<.05)。
- 胰腺内副脾的ADC MSR低于胰腺神经内分泌肿瘤(p<.001),R2* MSR高于胰腺神经内分泌肿瘤(p<.001)。
诊断标准与关键数值
- 标准3(0.9≤R2* MSR≤1.7):R1敏感度90.0%、特异度95.0%;R2敏感度90.0%、特异度100.0%。
- 标准1(增强MRI上脾脏等信号):R1敏感度45.0%、特异度100.0%;R2敏感度75.0%、特异度100.0%。
- 标准2(ADC MSR≤1.08):R1敏感度45.0%、特异度85.0%;R2敏感度45.0%、特异度90.0%。
- 标准3敏感度高于标准1(仅R1,p=.004),也高于标准2(R1和R2,p=.012);各标准间特异度无差异。
- 胰腺内副脾的诊断依据为99mTc标记热损伤红细胞闪烁显像摄取或CT/MRI特征性表现且稳定≥12个月;胰腺神经内分泌肿瘤经手术切除后组织病理学诊断。
临床应用与阅片要点
- R2* MSR可作为鉴别胰腺内副脾与胰腺神经内分泌肿瘤的MRI指标,其敏感度高于增强MRI脾脏等信号标准和ADC MSR标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the performance of R2* in distinguishing intrapancreatic accessory spleens (IPASs) from pancreatic neuroendocrine tumors (PNETs).
METHODS: Two radiologists (R1 and R2) retrospectively reviewed the MRIs of 20 IPAS and 20 PNET patients. IPASs were diagnosed with uptake on 99mTc labeled heat-damaged red blood cell scintigraphy or characteristic findings on CT/MRI and ≥ 12 month-long-stability. PNETs were histopathologically diagnosed with resection. Using McNemar test, sensitivities and specificities of the diagnostic criterion based on R2* mass-to-spleen ratio (MSR) were compared with those of the other criteria using contrast-enhanced (CE) MRI and apparent diffusion coefficient (ADC) MSR.
RESULTS: The study included 40 patients (median age, 54; interquartile range, 43-65; 24 men, 16 women). IPASs exhibited spleen-isointensity on T2WI, late arterial and portal phases, and diffusion-weighted images more frequently than PNETs (p <.05). ADC MSRs were lower (p <.001) and R2* MSRs were higher (p <.001) in IPASs compared to PNETs. For R1, sensitivity and specificity were 45.0% and 100.0% for criterion 1 (spleen-isointensity on CE-MRI); 45.0% and 85.0% for criterion 2 (ADC MSR ≤ 1.08); 90.0% and 95.0% for criterion 3 (0.9 ≤ R2* MSR ≤ 1.7). For R2, 75.0% and 100.0%; 45.0% and 90.0%; 90.0% and 100.0%. Criterion 3 showed higher sensitivity than criterion 1 for R1 (p =.004), and criterion 2 for R1 and R2 (p =.012). There was no difference in specificity.
CONCLUSION: For differentiating IPAS from PNET, R2* showed higher sensitivity than, and similar specificity to CE-MRI and ADC.
引用
- Kang JG, Park JH, Park MS, et al. Differentiation of intrapancreatic accessory spleen from pancreatic neuroendocrine tumor using MRI R2. Abdom Radiol (NY). 2025. PMID: 39841231. doi:10.1007/s00261-024-04758-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。